NextGen Sciences Appoints Steve Zolnay as Vice President of Business Development for North America
Ann Arbor, Michigan, US, and London, UK, 6 December 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has appointed Steve Zolnay as Vice President of Business Development for North America.
Zolnay, a graduate from Dartmouth College with a degree in Biology, started his professional career at the Dana Farber Cancer Institute in Boston Massachusetts where he investigated the over expression of the Her2/Neu oncogene and its roles in Breast Cancer. In 1990, he moved over to the business side of science. He has successfully held various sales and business development positions interacting with Pharmaceutical, Biotech and Academic Institutions. Key positions that Zolnay has held include: Director of Sales North America for The Automation Partnership Cell Culture Automation Division, Vice President Business Development for Nanostream and Worldwide Director of Sales for Blue Sky Biotech. He is also President of Protein Attachment Technologies, an early stage Biotech company focusing on membrane associated cancer targets.
Klaus Rosenau, Chairman and CEO of NextGen Group, commented: "Steve brings a rich scientific background, a deep understanding of the application of technologies and services to pharma, biotech and diagnostic product development. Steve also brings many strong personal connections to leaders within the industry and will be instrumental in generating value for our customers and shareholders in the growing biomarker market".
NextGen has continuously expanded its product offerings by introducing a series of technically validated human multiplex plasma assays for oncology and CSF assays for CNS diseases. NextGen's assays are based upon its multiple reaction monitoring (MRM) mass spectrometry platform that generate highly data with high specificity and precision which clients can utilize in their drug and diagnostic development programmes. The MRM platform can be used to assay proteins and modified proteins for which there are no antibodies and can thus circumvent the limitations of current antibody based technologies. NextGen expects to develop further oncology and CNS disease-focused assay panels, both as proprietary products and with other companies, through partnerships and collaborations.
- ENDS -
For more information please contact :
NextGen Group
Klaus Rosenau, Chairman and CEO
klaus.rosenau@nextgensciences.com
+49 160 551 6756
Seymour Pierce
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000
Notes to Editors
NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalised medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarkets.com) playing an important role. NextGen Sciences' products include Discovery Assays, CNS Assays, Oncology Assays and Custom Assays . For more information visit www.nextgensciences.com
